First,- and second-generation EGFR-tyrosine kinase inhibitors (TKIs), i.e., gefitinib, erlotinib, and afatinib, have been a very effective standard first-line treatment for patients with advanced EGFR mutant NSCLC for many years, producing a relevant improvement in progression-free survival (PFS) compared with chemotherapy [4,5,6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.